New Alzheimer's drug clears FDA advisory vote despite unknowns.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38870282.
- Also identified by DOI 10.1126/science.adr0291.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pivotal trial of Eli Lilly's donanemab leaves questions about how to prescribe it and minimize risks.
Medical subject headings
- Alzheimer Disease
- Antibodies, Monoclonal, Humanized
- Drug Approval
- United States Food and Drug Administration